Lupin Q4 Review - Downbeat Margins; Triggers For U.S. Awaited: ICICI Direct

Lupin Q4 Review - Downbeat Margins; Triggers For U.S. Awaited: ICICI Direct

Lupin Ltd.'s manufacturing site at Visakhapatnam. (Photo: Company website)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Lupin Ltd.’s revenues from U.S. remained subdued while profitability was hampered due to high other expenses and impairment charges (Rs 127 crore).

Lupin's sales were up 2.6% YoY to Rs 3883 crore. Ebitda was at Rs 226.5 crore, down 68% YoY with margins at 5.8% mainly due to multiple factors namely-

  1. higher input cost,

  2. double digit price erosion in U.S.,

  3. losartan recalls,

  4. Solosec litigation payment,

  5. lower operating leverage and

  6. higher freight cost.

Adjusted loss of Rs 525 crore versus profit of Rs 460 crore in Q4 FY21.

Click on the attachment to read the full report:

ICICI Direct Lupin Q4FY22 Result Update.pdf
Read Document

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

lock-gif
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Still Not convinced ?  Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
GET REGULAR UPDATES